GS
KLRS

Gilead Sciences’s Kalaris Therapeutics KLRS Stock Holding History

Gilead Sciences’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-317,789
Closed -$848K – 14
2025
Q2 		$848K Sell
317,789
-405,484
-56% -$1.83M 0.07% 12
2025
Q1 		$5.81M Hold
723,273
– – 0.49% 9
2024
Q4 		$6.99M Buy
+723,273
New +$10.9M 0.45% 10

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Gilead Sciences's KLRS Position: Q3 2025 in Review

Gilead Sciences sold out of Kalaris Therapeutics (KLRS) in Q3 2025, closing a stake of 317,789 shares — an estimated $848K sold.

Gilead Sciences first reported a position in KLRS in Q4 2024 and held it in 3 quarters. The position peaked at $6.99M in Q4 2024. 32 funds tracked by Wall St. Rank hold KLRS as of Q3 2025.

  • Gilead Sciences reported no remaining Kalaris Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Gilead Sciences sold 317,789 Kalaris Therapeutics shares in Q3 2025, an estimated $848K.
  • Gilead Sciences first reported a position in Kalaris Therapeutics in Q4 2024 and held it in 3 quarters.
  • Gilead Sciences's Kalaris Therapeutics position peaked at $6.99M in Q4 2024.
  • 32 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2025.

Based on Gilead Sciences's 13F filing for Q3 2025, filed 13 Nov 2025.